Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

179.55USD
18 Jul 2018
Change (% chg)

-- (--)
Prev Close
$179.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
263,586
52-wk High
$236.05
52-wk Low
$85.90

Latest Key Developments (Source: Significant Developments)

• BLUEBIRD BIO SAYS CELGENE AMENDED PHASE 2 STUDY PROTOCOL
Friday, 13 Jul 2018 

July 12 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO - CO, CELGENE CONTINUE TO ANTICIPATE A POTENTIAL APPROVAL OF BB2121 PRODUCT CANDIDATE IN RELAPSED & REFRACTORY MULTIPLE MYELOMA IN 2020.BLUEBIRD BIO SAYS CELGENE HAS AMENDED STUDY PROTOCOL FOR KARMMA STUDY, AN ONGOING PHASE 2 STUDY OF BB2121 PRODUCT CANDIDATE - SEC FILING.BLUEBIRD BIO - DOSE RANGE FOR KARMMA STUDY WILL BE 150 TO 450 X 10(6)CAR+ T CELLS AND ENROLLMENT WILL INCREASE TO UP TO 140 PATIENTS.BLUEBIRD BIO INC - IN ADDITION, CELGENE HAS AMENDED STUDY PROTOCOL FOR CRB-401, AN ONGOING PHASE I STUDY OF BB2121 PRODUCT CANDIDATE.BLUEBIRD BIO INC - ENROLLMENT FOR CRB-401 STUDY WILL BE INCREASED BY UP TO 20 PATIENTS, WITH A DOSE RANGE OF 150 TO 450 X 10(6)CAR+ T CELLS.  Full Article

FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy
Wednesday, 23 May 2018 

May 23 (Reuters) - bluebird bio Inc ::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY.BLUEBIRD BIO INC - BREAKTHROUGH THERAPY DESIGNATION IS SUPPORTED BY PRELIMINARY DATA FROM ONGOING PHASE 2/3 STARBEAM STUDY (ALD-102).  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share
Wednesday, 13 Dec 2017 

Dec 12 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICED UNDERWRITTEN PUBLIC OFFERING OF 3.2 MILLION SHARES OF ITS COMMON STOCK AT $185 PER SHARE​.  Full Article

Bluebird Bio Announces Proposed Public Offering Of Common Stock
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BLUEBIRD BIO INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $600 MILLION OF ITS COMMON STOCK.  Full Article

bluebird bio And TC BioPharm Announce Strategic Collaboration
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY.BLUEBIRD BIO INC - FINANCIAL TERMS OF AGREEMENT INCLUDE A $16 MILLION UPFRONT PAYMENT.BLUEBIRD BIO - FINANCIAL TERMS OF AGREEMENT ALSO INCLUDE POTENTIAL RESEARCH AND DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS.BLUEBIRD BIO - AS PART OF DEAL, TC BIOPHARM ALSO ELIGIBLE TO GET UNDISCLOSED TIERED ROYALTIES ON PRODUCT SALES.BLUEBIRD BIO INC - CO, TC BIOPHARM WILL WORK TOGETHER TO ADVANCE TC BIOPHARM'S LEAD CAR-ENGINEERED GAMMA DELTA T CELL PROGRAM INTO CLINICAL TRIALS.  Full Article

Bluebird Bio Acquires Manufacturing Facility In North Carolina
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS.  Full Article

Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Celgene Corp :Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma.Celgene Corp - ‍designations based on preliminary clinical data from ongoing phase i study of bb2121 in heavily pre-treated multiple myeloma​.Celgene Corp - ‍updated data from CRB-401 is scheduled to be presented at 59(th) annual meeting of american society of hematology in Atlanta​.  Full Article

bluebird bio reports qtrly ‍loss per share $1.73​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - bluebird bio Inc :bluebird bio reports third quarter 2017 financial results and recent operational progress.Q3 revenue $7.7 million versus I/B/E/S view $7.1 million.bluebird bio Inc qtrly ‍loss per share $1.73​.Q3 earnings per share view $-1.71 -- Thomson Reuters I/B/E/S.  Full Article

Bluebird Bio announces treatment of first patient with thalassemia drug
Wednesday, 14 Dec 2016 

Bluebird Bio Inc : Bluebird Bio Inc says also moving forward with plans to initiate northstar-3 (hgb-212), a phase 3 trial of lentiglobin drug product . Bluebird Bio Inc says this study will also be conducted under new manufacturing process, and is expected to begin enrolling patients in 2017 .Bluebird bio announces first patient treated with lentiglobintm drug product in northstar-2 (hgb-207) phase 3 trial of patients with transfusion-dependent β-thalassemia.  Full Article

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.